1、RewiR&DMaking more medicines that matterJanuary 2025RewiR&D:Making more medicines that matter is published by McKinseys Life Sciences Practice.McKinsey&Company1200 19th Street NWFl.10-11,Suite 1100Washington,DC 20036Editors:Jermey Matthews,Mark Staples,Gwyn HerbeinArt director:LEFFCommunications:Sha

2、nnon Ensor,Emily M.KiernanProject management:Wendy ZhangLead reach and engagement partner:Gregory GravesThis publication is not intended to be used as the basis for trading in the shares of any company or for undertaking any other complex or significant financial transaction without consulting appro

3、priate professional advisers.No part of this publication may be copied or redistributed in any form without the prior written consent of McKinsey&Company.Copyright 2025 McKinsey&Company.All rights reserved.ContentsMaking more medicines that matterProductivity in biopharmaceutical R&D has slumped for

4、 a decade or more.We propose a recipe for sustainable,value-creating innovation,even in the face of strengthening industry headwinds.Charting the path to patientsCareful development of asset strategy across the pharmaceutical R&D pipeline is increasingly important in embracing opportunities for inno

5、vation.How biopharmaceutical leaders optimize their portfolio strategiesLeading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward.Heres how.Strengthening the R&D operating model for pharmaceutical companiesRevisiting the operating model could help pharmaceut

6、ical companies improve R&D productivity.Accelerating clinical trials to improve biopharma R&D productivityBiopharma sponsors are seeking to accelerate clinical trials and reduce costs through a set of targeted actions aimed at improving patient and site engagement and enrollment productivity.Operati